Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and DevelopmentBusiness Wire • 01/09/23
Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson's Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical AntipsychoticsBusiness Wire • 01/03/23
Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023Business Wire • 12/21/22
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/02/22
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/02/22
Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season?Zacks Investment Research • 11/01/22
Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) StankovicBusiness Wire • 10/27/22
Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022Business Wire • 10/20/22
Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of DirectorsBusiness Wire • 10/13/22
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer's SubjectsBusiness Wire • 10/05/22
Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett RevealedBusiness Wire • 10/04/22
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's TypeBusiness Wire • 09/29/22
Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDABusiness Wire • 09/12/22
Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/07/22
Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to TradeZacks Investment Research • 08/30/22